Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07555938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Study acronym: CEVOLUTION
StatusRecruiting
PhasePhase 3
Started2026-06-23
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status, Contacts/Locations v5
Trial sites expanded: 40 → 75 locations
2026-08-13
Study Status, Contacts/Locations v4
Trial sites expanded: 15 → 40 locations
2026-07-17
Study Status, Contacts/Locations v3
Trial sites expanded: 7 → 15 locations
Start dateestimated 2026-06-30→confirmed 2026-06-23
2026-06-19
Study Status, Contacts/Locations, References v2
Trial sites expanded: 4 → 7 locations
2026-05-22
Study Status, Contacts/Locations v1
Recruitment opened
Trial sites expanded: 0 → 4 locations
Primary completion moved earlier: 2029-06-29 → 2028-10-31
Completion pushed: 2032-12-31 → 2033-01-31
Start date2026-05-01→2026-06-30
2026-04-22
Original filing
Roche/Genentech
364 trials monitored
See 34 trials at risk
Multiple Myeloma
1,228 trials monitored
See 75 trials at risk
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Trial Details
NCT Number NCT07555938
Lead Sponsor Hoffmann-La Roche
Conditions Multiple Myeloma
Enrollment 380 participants
Start Date 2026-06-23
Primary Completion 2028-10-31 (estimated)
Study Completion 2033-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-11